Registreerimine

 

Registreerimine 

eriarsti vastuvõtule

(vajalik isikukood)

 

1) Tel 731 9100

   (E-R 07.30-18.00) 

2) internetis Kliinikumi broneerimisvormi kaudu

3) Kliinikumi      patsiendiportaalis

 ePatsient

 

 

Vastuvõtuaega saab tühistada telefonil 731 9099

Kliinikumi üldinfo

 

Telefon 731 8111
E-P kell 08.00 – 19.00

Kontaktandmed

SA Tartu Ülikooli Kliinikum
Hematoloogia-onkoloogia kliinik
Puusepa 8, 
51014 TARTU

Tel:  +372 731 9802
Fax: +372 731 9804

e-post: ho@kliinikum.ee

Puusepa 8 majajuht

2017

 

Jrk

Autor

Pealkiri

Allikas

1

van Gelder M., de Wreede LC., Bornhäuser M., Niederwieser D., Karas M., Anderson NS., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen JJ., Yakoub-Agha I., Russell NH., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., van Biezen A., Henseler A., Schönland S., Kröger N., Schetelig J., Chronic Malignancy Working Party group
Autorite grupp:Everaus H.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

Bone Marrow Transplantation: 52 (3), 372-380, 2017

2

Ikemoto H., Lingasamy P., Anton Willmore AM., Hunt H., Kurm K., Tammik O., Scodeller P., Simon-Gracia L., Kotamraju VR., Lowy AM., Sugahara KN., Teesalu T.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis

Tumor Biology: 39 (5), 1-9, 2017

3

Takkis K., Aro R., Kõrgvee LT., Varendi H., Lass J., Herodes K., Kipper K.

Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives

Analytical and Bioanalytical Chemistry: 409 (12), 3145-3151, 2017

4

Padrik P., Valter A., Valter E., Baburin A., Innos K.

Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study

Acta Oncologica: 56 (1), 52-58, 2017

5

Paapsi K., Mägi M., Mikkel S., Saks K., Aareleid T., Innos K.

The impact of under-reporting of cases on the estimates of childhood cancer incidence and survival in Estonia

European Journal of Cancer Prevention: 26, S147-S152, 2017

6

Ojamaa K., Veerus P., Baburin A., Everaus H., Innos K.

Time Trends in Ovarian Cancer Survival in Estonia by Age and Stage

International Journal of Gynecological Cancer: 27 (1), 44-49, 2017

7

Sak K., Everaus H.

Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids

Current Genomics: 18 (1), 3-26, 2017

8

Saar M., Jaal J., Johnson JB.

Do pharmacists need additional education to support patients on oral chemotherapy?

European Journal of Oncology Pharmacy: 10 (1), 6-11, 2017

9

Hoffmann VS., Baccarani M., Hasford J., Castagnetti F., Di Raimondo F., Casado LF., Turkina A., Zackova D., Ossenkoppele GJ., Zaritskey A., Höglund M., Simonsson B., Indrak K., Sninska Z., Sacha T., Clark RE., Bogdanovic A., Hellmann A., Griškevičius L., Schubert-Fritschle G., Sertic D., Guilhot J., Lejniece S., Zupan I., Burgstaller S., Koskenvesa P., Everaus H., Costeas P., Lindoerfer D., Rosti G., Saussele S., Hochhaus A., Hehlmann R.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Leukemia: 31 (3), 593-601, 2017

10

Wolthers BO., Frandsen TL., Abrahamsson J., Albertsen BK., Helt LR., Heyman M., Jonsson OG., Kõrgvee LT., Lund B., Raja RA., Rasmussen KK., Taskinen M., Tulstrup M., Vaitkevičiene GE., Yadav R., Gupta R., Schmiegelow K.

Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol

Leukemia: 31 (2), 325-332, 2017

11

Minajeva A., Kase M., Saretok M., Adamson-Raieste A., Kase S., Niinepuu K., Vardja M., Asser T., Jaal J.

Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients

Neuroscience Journal: 2017, Artikkel nr 5629563, 2017

12

Sarana B., Jaal J., Tamm H., Laisaar T.

Resection of unicentric interlobar Castleman disease with following adjuvant radiotherapy

SAGE Open Medical Case Reports: 5, 2050313X17744481, 2017

13

Jaal J., Kase M., Junninen J., Niinepuu K., Saar M., Jaal J.

Immuunravi ja kiiritusravi – uus efektiivne kombinatsioon

Eesti Arst: 96 (5), 296-302, 2017

14

Junninen J., Saar M., Niinepuu K., Jaal J., Kase M., Jaal J.

Uued ravimid – uued kõrvaltoimed

Eesti Arst: 96 (5), 289-295, 2017

15

Niinepuu K., Junninen J., Saar M., Jaal J., Kase M., Jaal J.

Immuunravi – uus suund onkoloogias

Eesti Arst: 96 (5), 281-286, 2017

16

Padrik P., Valter E., Innos K., Valter A., Baburin A.

Erialauudised. Onkoloogia. Maliigse nahamelanoomi esinemissagedus ning elulemus Eestis

Eesti Arst: 96 (2), 111-111, 2017

17

Sinisalu V., Vetkas A., Hein M., Loorits D.

Koljusisesed verevalumid tõelise polütsüteemiaga haigel kerge trauma järel

Eesti Arst: 96 (8), 474-477, 2017

18

Nowakowski GS ., Kalakonda N., Truemper L., Everaus H., Fustier P., Jaeger J., Manzke O., Jaeger U.

Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma

Journal of Clinical Oncology: 35 (Suppl 15), Tees nr TPS7573, 2017

19

Aaspõllu H., Vapper A., Saar M., Jaal J., Mägi L., Kase M., Minajeva A., Vooder T., Roosipuu R., Jaal J.

Immuunkontrollpunktide PD-1 ja PD-L1 ekspressioon mitteväikerakulise kopsuvähi koes sõltub DNA reparatsioonist

Eesti Arst: 96 (Lisa 1), 19-19, 2017

20

Sak K., Lust H., Kase M., Jaal J.

Flavonoid kvertsetiini metüülmetaboliitide tsütotoksiline toime inimese kopsuvähi rakuliinides

Eesti Arst: 96 (Lisa 1), 48-48, 2017

21

Sak K., Lust H., Kase M., Saar M., Jaal J.

Flavonoid hesperetiin inhibeerib taksaanide tsütotoksilist toimet inimese eesnäärmevähirakkudes PPC-1

Eesti Arst: 96 (Lisa 1), 25-25, 2017

22

Palover M., Leitsalu L., Reigo A., Nikopensius T., Vaiküll K., Kals M., Padrik P., Esko T., Metspalu A., Tõnisson N.

Genetics-first analysis of high-risk variants for breast, ovarian and prostate cancer in participants of Estonian Genome Center

European Human Genetics Conference 2017, 27–30 May 2017: Tees nr C01.6, 2017

23

Jaal J.

Immuunsüsteem ja vähk

Eesti Arst: 96 (5), 251-251, 2017

24

Vaasna I.

Günekoloogilised pahaloomulised kasvajad

Perearst: 3 (123), 47-51, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2016

 

 

Ator

Pealkiri

Allikas

1

Harrison SJ., Mainwaring P., Price T., Millward MJ., Padrik P., Underhill CR., Cannell PK., Reich SD., Trikha M., Spencer A.

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

Clinical Cancer Research: 22 (18), 4559-4566, 2016

2

Simon-Gracia L., Hunt H., Scodeller P., Gaitzsch J., Kotamraju VR., Sugahara KN., Tammik O., Ruoslahti E., Battaglia G., Teesalu T.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes

Biomaterials: 2104, 247-257, 2016

3

Soplepmann J., Laidre P.

Teenage colorectal polyposis and cancer may be caused by constitutional mismatch repair deficiency (CMMRD)

Acta Oncologica: 55 (12), 1503-1505, 2016

4

Reima H., Saar H., Innos K., Soplepmann J.

Methylene blue intra-arterial staining of resected colorectal cancer specimens improves accuracy of nodal staging: A randomized controlled trial

European Journal of Surgical Oncology: 42 (11), 1642-1646, 2016

5

Sak K., Everaus H.

Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids

Current Drug Metabolism: 17 (6), 528-541, 2016

6

Sak K., Kasemaa K., Everaus H.

Potentiation of luteolin cytotoxicity by flavonols fisetin and quercetin in human chronic lymphocytic leukemia cell lines

Food & Function: 7 (9), 3815-3824, 2016

7

Kase M., Adamson A., Saretok M., Minajeva A., Vardja M., Jõgi T., Asser T., Jaal J.

Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme

Journal of Neurosurgical Sciences: 60 (4), 417-423, 2016

8

Innos K., Valvere V., Padrik P., Eelma E., Kütner R., Lehtsaar J., Tekkel M.

Mammography Use and Mode of Detection Among Breast Cancer Patients in Estonia

Women & Health: 56 (2), 129-140, 2016

9

Hulegardh E., Punab M., Holmberg E., Palk K., Laane E., Everaus H., Wennström L., Stockelberg D.

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years

Acta Haematologica: 136 (3), 167-173, 2016

10

Linjama T., Impola U., Niittyvuopio R., Kuittinen O., Kaare A., Rimpiläinen J., Volin L., Peräsaari J., Jaatinen T., Lauronen J., Saarinen T., Juvonen E., Partanen J., Koskela S.

Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region

HLA: 87 (5), 350-355, 2016

11

Saar M., Jaal J., Johnson JB.

Do pharmacists need additional education to support patients on oral chemotherapy?

European Journal of Oncology Pharmacy: 10 (1), 6-11, 2016

12

Pintson M., Hein M.

Hulgimüeloomi ravi

Eesti Arst: 95 (8), 547-551, 2016

13

Laidre P., Soplepmann J.

Pärilik vähk: diagnoos kinnitatud 23 aastat hiljem

Eesti Arst: 95 (9), 610-613, 2016

14

Laane E., Raudsepp K., Everaus H., Punab M.

Efficacy of Generic Imatinib in Newly Diagnosed Cp-Cml Patients in Estonian Population

Haematologica: 101 (Suppl 1), 741-741, 2016

15

Linjama T., Impola U., Niittyvuopio R., Kuittinen O., Kaare A., Rimpiläinen J., Volin L., Peräsaari J., Jaatinen T., Lauronen J., Saarinen T., Juvonen E., Partanen J., Koskela S.

Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region

Scandinavian Journal of Immunology: 83 (5), 363-363, 2016

16

Murumägi A., Hirasawa A., Khan S., Arjama M., Pellinen T., Koivisto-Korander R., Leminen A., Mägi A., Aittokallio T., Butzow R., Kallioniemi O.

Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells

International Journal of Gynecological Cancer: 26 (Suppl 3), 653-653, 2016

17

Saar M., Sei II., Jaal J.

Underutilization of G-CSF in elderly cancer patients – an issue that needs to be urgently addressed

Annals of Oncology: 27 (Suppl 6), Tees nr 1456P, 2016

18

Jaal J., Mägi L., Jõgi T., Kase M., Minajeva A., Markus V., Vooder T., Roosipuu R., Jaal J.

Expression of DNA-PK in squamous cell lung cancer has gender differences and depends on smoking

Radiotherapy and Oncology: 119 (Suppl 1), S969-S969, 2016

19

Tõnisson N., Nikopensius T., Vaiküll K., Leitsalu L., Kals M., Padrik P., Esko T., Metspalu A.

Actionable mutations in the whole-genome sequenced gene donors of Estonian Genome Center

European Journal of Human Genetics: 24 (E-Suppl 1), 391-391, 2016

20

Sak K., Kasemaa K., Everaus H.

Flavonoidide tsütotoksiliste toimete sünergilised mehhanismid kroonilise lümfoleukeemia rakkudes

Eesti Arst: 95 (Lisa 2), 20-20, 2016

21

Sei II., Saar M., Jaal J.

Granulotsüütide kolooniaid stimuleerivate faktorite kasutamine kasvajaliste haigustega patsientidel Tartu Ülikooli Kliinikumis

Eesti Arst: 95 (Lisa 2), 47-47, 2016

22

Tõnisson N., Nikopensius T., Vaiküll K., Leitsalu L., Kals M., Padrik P., Esko T., Metspalu A.

Actionable mutations in the wholegenome sequenced gene donors of the Estonian Biobank

Eesti Arst: 95 (Lisa 1), 62-62, 2016

23

Mikkel S., Saks K.

Kõrgmaliigsed luusarkoomid lastel

Eesti Lastearstide Seltsi XXI kongress 2.–4. juuni 2016, Tallinn: 55-55, 2016

24

Pruunsild K., Saks K., Orgulas K., Mikkel S.

Lapseea hemofiilia käsitlus Eestis aastatel 2001- 2016

Eesti Lastearstide Seltsi XXI kongress 2.–4. juuni 2016, Tallinn: 64-64, 2016

25

Saks K., Mikkel S.

Lapseea kesknärvisüsteemi kasvajad Eestis 2003-2014

Eesti Lastearstide Seltsi XXI kongress 2.–4. juuni 2016, Tallinn: 39-39, 2016

26

Saar M., Sei II., Jaal J.

Usage of granylocyte colony stimulating factors to reduce the risk of febrile neutropenia – are our patients safe?

European Journal of Oncology Pharmacy: 10 (Suppl), 54-54, 2016

27

Hoffmann VS., Baccarani M., Hasford J., Castagnetti F., Di Raimondo F., Casado LF., Turkina A., Zackova D., Ossenkoppele G., Zaritskey A., Höglund M., Simonsson B., Indrak K., Sninska Z., Sacha T., Clark R., Bogdanovic A., Hellmann A., Griskevicius L., Schubert-Fritschle G., Sertic D., Guilhot J., Lejniece S., Zupan I., Burgstaller S., Koskenvesa P., Everaus H., Costeas P., Lindoerfer D., Rosti G., Saussele S., Hochhaus A., Hehlmann R.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Leukemia, 2016

 

  

2015

  • Sak,K., Everaus, H Use of murine L1210 and P388 lymphocytic leukemia cells in cytotoxic studies of flavonoid.International Journal of Phytomedicine, 7 (2), 131−135
  • Jaal, J.; Kase, M.; Minajeva, A.; Saretok, M.; Adamson, A.; Lukjanova, J.; Metsaots, T.; Jõgi, T.; Joonsalu, M.; Vardja, M.; Asser, T. VEGFR-2 expression in glioblastoma multiforme depends on inflammatory tumor microenvironment. Int J of Inflammation Int J of Inflammation, volume 2015, Article ID 385030
  • Borras, JM.; Lievens, Y.; Dunscombe, P.; Coffey, M.; Malicki, J.; Corral, J.; Gasparotto, C.; Defourny, N.; Barton, M.; Verhoeven, R.; van Eycken, L.; Primic-Zakelj, M.; Trojanowski, M.; Strojan, P.; Grau, C.; Kokobobo, A.; Sedlmayer, F.; De Hertogh, O.; Peltzer – La Tourelle, CH.; Hadjieva, T.; Petera, J.; Eriksen, JG.; Jaal, J.; Azria, D.; Takacsi-Nagy, Z. et al The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HEROanalysis. Radiotherapy and Oncology, 116(1), 38 – 44
  • Hoffmann VS., Baccarani M., Hasford J., Lindoerfer D., Burgstaller S., Sertic D., Costeas P., Mayer J., Indrak K., Everaus H., Koskenvesa P., Guilhot J., Schubert-Fritschle G., Castagnetti F., Di Raimondo F., Lejniece S., Griškevičius L., Thielen N., Sacha T., Hellmann A., Turkina A., Zaritskey A., Bogdanovic A., Sninska Z., Zupan I., Steegmann JL., Simonsson B., Clark RE., Covelli A., Guidi G., Hehlmann R. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia: 29 (6), 1336-1343, 2015
  • Innos K., Padrik P., Valvere V., Aareleid T. Sex differences in cancer survival in Estonia: a population-based study. BMC Cancer: 15, Artikkel nr 72, 2015
  • Sathitruangsak C., Righolt CH., Klewes L., Tammur P., Ilus T., Tamm A., Punab M., Olujohungbe A., Mai S. Quantitative Superresolution Microscopy Reveals Differences in Nuclear DNA Organization of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Journal of Cellular Biochemistry: 116 (5), 704-710, 2015
  • Sak K., Everaus H. Multi-target cytotoxic actions of flavonoids in blood cancer cells. Asian Pacific journal of cancer prevention: 16 (12), 4843-4847, 2015
  • Sak K., Everaus H. Chemomodulating effects of flavonoids in human leukemia cells. Anti-Cancer Agents in Medicinal Chemistry: 15 (9), 1112-1126, 2015
  • Sak K., Everaus H. Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells. Current Stem Cell Research & Therapy: 10 (3), 271-282, 2015
  • Sak K., Lust H., Everaus H. Cytotoxic action of flavonoids in human burkitt’s lymphoma cell lines and its antiandrogenic modulation. International Journal of Toxicological and Pharmacological Research: 7 (2), 108-115, 2015
  • Jaal J., Jõgi T., Altraja A. Small Cell Lung Cancer Patient with Profound Hyponatremia and Acute Neurological Symptoms. Case Reports in Oncological Medicine: Artikkel nr UNSP 286029, 2015
  • Sak, K., Everaus, H. Gender-dependent metabolism of flavonoids as a possible determinant of cancer risk. Austin Journal of Nutrition & Metabolism
  • Jaal J. Eakad ja vähk. Eesti Arst: 94 (10), 579-579, 2015
  • Jaal J., Kase M., Jõgi T., Tammaru M., Ojamaa K., Mägi M. Vähihaigestumus Eesti eakate hulgas ajavahemikul 1980–2012. Eesti Arst: 94 (10), 583-587, 2015
  • Metsaots T., Jaal J. Neeru- ja maksapuudulikkus ning vähk. Eesti Arst: 94 (10), 608-612, 2015
  • Pihlak R., Jaal J. Diabeet ja vähk. Eesti Arst: 94 (10), 619-622, 2015
  • Sak K., Lust H., Everaus H. Tetrasoolium- (MTT) metoodika võimaldab uurida potentsiaalselt aktiivsete ühendite kemosensitiivsust ja –resistentsust. Eesti Arst: 94 (8), 472-477, 2015
  • Saretok M., Jaal J. Hüpertensioon ja vähk. Eesti Arst: 94 (10), 614-617, 2015
  • Laidre P., Soplepmann J., Uibo O., Raime K., Yakoreva M., Mirka G., Roomere H., Õunap K. Perekondlik adenomatoosne polüpoos: ülevaade ja ühe perekonna haigusjuht. Eesti Arst: 94 (1), 38-43, 2015
  • Kase M. Glioblastoma multiforme: possibilities to improve treatment efficacy . Dissertationes medicinae Universitatis Tartuensis: 232, 136, 2015
  • Hoffmann VS., Baccarani M., Hasford J., Lindoerfer D., Burgstaller S., Sertic D., Costeas P., Mayer J., Indrak K., Everaus H., Koskenvesa P., Guilhot J., Schubert-Fritschle G., Castagnetti F., Di Raimondo F., Lejniece S., Griškevičius L., Thielen N., Sacha T., Hellmann A., Turkina A., Zaritskey A., Bogdanovic A., Sninska Z., Zupan I., Steegmann JL., Simonsson B., Clark RE., Hehlmann R. Analysis of Treatment and Outcome Data of 2904 Patients from the Eutos Population-Based Registry . Haematologica: 100 (Suppl 1), 181-181, 2015
  • Jaal J., Jõgi T., Kase M., Ojamaa K., Tammaru M., Mägi M., Asser T. Incidence of solid tumors in Estonian 15-19-year old adolescents. European Journal of Cancer: 51 (Suppl 3), S160-S160, 2015
  • Joonsalu M., Kase M., Minajeva A., Junninen J., Metsaots T., Niinepuu K., Vardja M., Kase S., Asser T., Jaal J. Expression of insulin growth factor-1 receptor (IGF-1R) is associated with cancer stem-like cells and tumor microenvironment. European Journal of Cancer: 51 (Suppl 3), S588-S588, 2015
  • Teras J., Teras M., Mägi A., Pata P., Teras RM. Complete lymph node dissection for Stage III malignant melanoma: Reducing morbidity. European Journal of Cancer: 51 (Suppl 3), S671-S671, 2015
  • Laane E., Nanjappa P., Kumar S., Magrangeas F., Minvielle S., Everaus H., Anderson KC., Avet-Loiseau H., Shammas MA., Munshi NC. XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells. Blood: 126 (23), 1218 - 1218, 2015
  • Hoffmann VS., Baccarani M., Hasford J., Lindoerfer D., Burgstaller S., Sertic D., Costeas P., Mayer J., Indrak K., Everaus H., Koskenvesa P., Guilhot J., Schubert-Fritschle G., Castagnetti F., Di Raimondo F., Lejniece S., Griskevicius L., Thielen N., Sacha T., Hellmann A., Turkina A., Zaritskey A., Bogdanovic A., Sninska Z., Zupan I., Casado F., Simonsson B., Clark RE., Saussele S., Hochhaus A., Hehlmann R. Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. Blood: 126 (23), 2780 - 2780, 2015
  • Ali HMM., Everaus H. Immune and hormonal peculiarities and gender related changes in Multiple myeloma patients. Clinical Lymphoma Myeloma and Leukemia: 15 (Suppl 3), e255-e256, 2015
  • Jaal J., Mägi L., Jõgi T., Kase M., Minajeva A., Vardja M., Vooder T., Roosipuu R., Jaal J. DNA reparatsiooniensüümi DNA-PK ekspressioon on lamerakulise kopsuvähi koes naistel madalam kui meestel. Eesti Arst: 94 (Lisa 3), 16-16, 2015
  • Kahre T., Tõnisson N., Roosipuu R., Kallandi Ü., Jõgi T., Jaal J. Epidermaalse kasvufaktori retseptori mutatsioonide esinemine mitteväikerakulise kopsuvähi koes. Eesti Arst: 94 (Lisa 3), 19-19, 2015
  • Sarv S., Kõks S., Salumets A., Padrik P., Reimann E. Munasarjavähi molekulaarsete markerite detekteerimine IonTorrenti vähipaneeliga. Eesti Arst: 94 (Lisa 3), 20-20, 2015
  • Rahu M. Kobalamiini ehk B12-vitamiini defitsiit. Apteeker: 1 (77), 15-19, 2015
  • Mikkel S. Pahaloomulised kasvajad lastel. Perearst: 3 (101), 54-59, 2015
  • Padrik P. Täppismeditsiin onkoloogias. Perearst: 8 (106), 37-38, 2015
  • Innos K., Valvere V., Padrik P., Eelma E., Kütner R., Lehtsaar J., Tekkel M. Mammography Use and Mode of Detection Among Breast Cancer Patients in Estonia Women Health, 2015

 

2014

  • Dunscombe P., Grau C., Defourny N., Malicki J., Borras JM., Coffey M., Bogusz M., Gasparotto C., Slotman B., Lievens Y., HERO Consortium Autorite grupp:Jaal J. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. Radiotherapy and Oncology: 112 (2), 165-177, 2014

  •  Grau C., Defourny N., Malicki J., Dunscombe P., Borras JM., Coffey M., Slotman B., Bogusz M., Gasparotto C., Lievens Y., Health Economics in Radiation Oncology (HERO) Consortium

    Autorite grupp:Jaal J. Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiotherapy and Oncology: 112 (2), 155-164, 2014

  •  Lievens Y., Defourny N., Coffey M., Borras JM., Dunscombe P., Slotman B., Malicki J., Bogusz M., Gasparotto C., Grau C., Health Economics in Radiation Oncology (HERO) Consortium

    Autorite grupp:Jaal J. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiotherapy and Oncology: 112 (2), 178-186, 2014

  •  Baburin A., Aareleid T., Padrik P., Valvere V., Innos K. Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage. Acta Oncologica: 53 (2), 226-234, 2014

    Pihlak R., Liivand R., Trelin O., Neissar H., Peterson I., Kivistik S., Lilo K., Jaal J. Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling. European Journal of Cancer Care: 23 (2), 249-254, 2014

  •  Jakobson T., Karjagin J., Vipp L., Padar M., Parik AH., Starkopf L., Kern HR., Tammik O., Starkopf J. Postoperative complications and mortality after major gastrointestinal surgery. Medicina (Lithuania): 50 (2), 111–117, 2014

  •  Adamson A., Jaal J. Fertiilsuse säilitamine noortel vähihaigetel. Eesti Arst: 93 (7), 418-422, 2014

  • Jaal J. Noored ja vähk. Eesti Arst: 93 (7), 367-367, 2014

  •  Jaal J., Kase M., Jõgi T., Tammaru M., Ojamaa K., Mägi M. Vähihaigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst: 93 (7), 369-373, 2014

  • Jaal J., Kase M., Jõgi T., Tammaru M., Ojamaa K., Mägi M. Kilpnäärmevähki haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 414-417, 2014

  • Joonsalu M., Mägi M., Kase M., Jõgi T., Tammaru M., Ojamaa K., Asser T., Jaal J. Peaaju primaarsetesse pahaloomulistesse kasvajatesse haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009. Eesti Arst: 93 (7), 410-413, 2014

  • Jõgi T., Mägi M., Kase M., Tammaru M., Ojamaa K., Jaal J.Kopsuvähki haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 381-384, 2014
  • Kuusk G., Mägi M., Kase M., Jõgi T., Tammaru M., Ojamaa K., Jaal J.Naha pahaloomulistesse kasvajatesse haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 386-390, 2014
  • Niinepuu K., Mägi M., Kase M., Jõgi T., Tammaru M., Ojamaa K., Jaal J.Eesnäärmevähki ja munandivähki haigestumus 15–44aastaste Eesti meeste hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 399-402, 2014
  • Ojamaa K., Tammaru M., Kase M., Mägi M., Jõgi T., Jaal J. Rinnavähki haigestumus 15–44aastaste Eesti noorte naiste hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 391-393, 2014
  • Ojamaa K., Tammaru M., Kase M., Mägi M., Jõgi T., Jaal J. Günekoloogilistesse pahaloomulistesse kasvajatesse haigestumus 15–44aastaste Eesti noorte naiste hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 395-398, 2014
  • Padrik P., Soplepmann J., Hussar K., Teras J., Teras M., Putnik K., Ojamaa K., Adamson A., Saretok M. Kliinilise auditi „Naha melanoomi diagnostika ja ravi 2012. aastal esmashaigestunud patsientidel” kokkuvõte. Eesti Arst: 93 (8), 445-447, 2014
  • Pihlak R., Mägi M., Kase M., Jõgi T., Tammaru M., Ojamaa K., Jaal J. Neeruvähki ja kusepõievähki haigestumus 15–44aastaste Eesti inimeste hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 405-408, 2014
  • Saretok M., Mägi M., Kase M., Jõgi T., Tammaru M., Ojamaa K., Jaal J. Maovähki ja kolorektaalvähki haigestumus 15–44aastaste Eesti noorte hulgas ajavahemikul 1980–2009 Eesti Arst: 93 (7), 375-379, 2014
  • Tillmann V., Talvik T., Teek R., Joost K., Talvik I., Mikkel S., Lüüs SM., Stelmach T., Gross-Paju K., Sander V., Habicht A., Sõukand R., Taks H., Haukanõmm M., Vabamäe I., Õunap K. Eesti haruldaste haiguste arengukava koos tegevusplaaniga aastateks 2015–2017 Eesti Arst: 93 (5), 291-295, 2014
  • Lindoerfer D., Hoffmann VS., Rosti G., Castagnetti F., Saussele S., Guilhot J., Simonsson B., Steegmann JL., Mayer J., Indrak K., Turkina AG., Zaritskey A., Labar B., Zupan IP., Thielen N., Clark RE., Thaler J., Melanthiou F., Everaus H., Porkka K., Bogdanovic A., Schubert-Fritschle G., Panagiotidis P., Masszi T., Lejniece S., Griskevicius L., Hellmann A., Prejzner W., Sacha T., Almeida A., Dyagil I., Colita A., Mihaylov G., Hehlmann R., Hasford J., Baccarani M. The eutos population-based registry : evaluation of baseline characteristics and first treatment choices of 2983 newly diagnosed chronic myeloid leukemia (Cml) patients from 20 European countries. Haematologica: 99 (Suppl 1), 238-239, 2014
  • Baccarani M., Hoffmann VS., Rosti G., Castagnetti F., Saussele S., Guilhot J., Simonsson B., Steegmann JL., Mayer J., Indrak K., Turkina AG., Zaritskey A., Labar B., Zupan I., Thielen N., Clark RE., Thaler J., Melanthiou F., Everaus H., Porkka K., Bogdanovic A., Schubert-Fritschle G., Panagiotidis P., Masszi T., Lejniece S., Griskevicius L., Hellmann A., Prejzner W., Sacha T., Almeida A., Dyagil I., Colita A., Mihaylov G., Hehlmann R., Hasford J., Lindoerfer D. Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials Blood: 124 (21), Tees nr 3160, 2014
  • Hoffmann VS., Lindoerfer D., Thaler J., Labar B., Melanthiou F., Mayer J., Everaus H., Guilhot J., Schubert-Fritschle G., Castagnetti F., Lejniece S., Griskevicius L., Thielen N., Sacha T., Hellmann A., Turkina A., Zaritskey A., Bogdanovic A., Indrak K., Zupan I., Steegmann JL., Simonsson B., Clark R., Hoglund M., Hehlmann R., Hasford J., Baccarani M. Incidence of CML in Europe - a Comparison of 19 European Countries with US SEER Data Blood: 124 (21), Tees nr 3145, 2014
  • Jürgens H., Tiigi R., Ojamaa K., Pokker H., Innos K., Padrik P. A population-based analysis of changes in therapy of metastatic renal cell carcinoma (mRCC) 2014 ASCO Annual Meeting: Artikkel nr e15586, 2014
  • Ali HMM., Everaus H. Multiple myeloma with end stage renal failure treatment challenges. BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 46-47, 2014
  • Everaus H. Future of the hematopoietic stem cell transplantation, lessons learned BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 31-32, 2014
  • Hein M., Kõdar H., Rätsep O., Varik M. PH-negative chronic myeloproliferative disorders in Estonia 2009-2013 BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 44 - 44, 2014
  • Hein M., Viigimaa I. Clinical experience with thrombopoietin receptor agonists in Estonia. BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 27-27, 2014
  • Kõrgvee LT., Mikkel S., Leismann T., Everaus H. Autoimmune lymphoproliferative syndrome in 17-years-old boy: case report BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 41-42, 2014
  • Laane E., Raudsepp K., Everaus H., Punab M. Outcome of the first line imatinib treatment of CP-CML in Estonia BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 43-44, 2014
  • Mikkel S., Kaare A., Lehtmaa J., Everaus H. All relapse after allogeneic bone marrow transplantation: case report BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 38-39, 2014
  • Pruunsild K., Mikkel S., Orgulas K., Saks K. Estonian experience in useing NOPHO ALL 2008 protocol for children BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 59-59, 2014
  • Punab M., Palk K. Outcome in adults with all treated by NOPHO 2008 protocol in Estonia BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 37-38, 2014
  • Rahu M., Loigom D., Trats T. Primary central nervous system lymphoma treated in Estonia 2008-2013 BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 51-51, 2014
  • Saks K., Mikkel S., Pruunsild K. Treatment of childhood AML by NOPHO protocols, Estonian results BCH 2014, 9th Baltic Conference of Hematology 24 -26 April 2014. Final Programme and Abstract Book: 29-29, 2014
  • Reima H., Saar H., Soplepmann J. Methylene blue ex vivo staining of resected colorectal cancer specimens to enhance lymph node retrieval - randomized controlled trial Book of Abstracts, 6th Baltic Congess of Oncology "Multidisciplinary Approach in Cancer Care": 87-87, 2014
  • Joonsalu M., Saretok M., Adamson A., Lukjanova J., Metsaots T., Jõgi T., Kase M., Minajeva A., Vardja M., Asser T., Jaal J. Angiogeneesi inhibiitorite ühe sihtmärgi – VEGFR2 – ekspressioon sõltub kasvaja mikrokeskkonnast. Eesti Arst: 93 (Lisa 1), 9-9, 2014
  • Männik A., Lutsar K., Kaare A., Kiivet RA. Müeloomtõve ravimite kulutõhusus. Eesti Arst: 93 (Lisa 1), 34-34, 2014
  • Sažko A., Jõgi T., Vardja M., Jaal J. 4-dimensionaalse kompuutertomograafia alusel planeeritav kopsuvähi radiokemoteraapia on ohutum Eesti Arst: 93 (Lisa 1), 17-17, 2014
  • Everaus H. Closer to personalized approach through accepting the gender differences in medicine. EPMA Journal: 5 (Suppl 1), A148-A148, 2014
  • Everaus H. Hematopoietic stem cell transplantation (HSCT) as an example of personalized approach in the management of individual disease EPMA Journal: 5 (Suppl 1), A62-A62, 2014
  • Roomere H., Laidre P., Uibo O., Soplepmann J., Mirka G., Yakoreva M., Kahre T., Õunap K. Familial adenomatous polyposis – case report in Estonia. Journal of International Education for Clinical Chemistry and Laboratory Medicine (IECCLM): 1 (1), 37-37, 2014
  • Varendi H., Lass J., Kõrgvee LT., Turner MA., Vaes WHJ., van Duijn E., PAMPER consortium. Phramacokinetics of oral 14C paracetamol as microtracer and microvolumes in infants Journal of Pediatric and Neonatal Individualized Medicine: 4 (1), 129-129, 2014
  • Medvedeva K., Varendi ML. Tsütostaatikumide ohutu käsitlemine Eesti Õde: 3, 20-22, 2014
  • Valkonen L., Müürsepp E., Urban R. Tartu Tervishoiu Kõrgkooli neljanda kursuse õe õppekava üliõpilaste arusaam hoolivusest õenduses ja hoolivuse kujunemisest. Eesti Õde: 3, 5-6, 2014
  • Lehtsaar J. Rinnaarsti nõuanded ja soovitused perearstidele Perearst: 10 (97), 107-110, 2014
  • Punab M. Reaktiivsed valgeveremuutused Perearst: 11 (98), 53-56, 2014
  • Sathitruangsak C., Righolt CH., Klewes L., Tammur P., Ilus T., Tamm A., Punab M., Olujohungbe A., Mai S. Quantitative Superresolution Microscopy Reveals Differences in Nuclear DNA Organization of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Journal of Cellular Biochemistry, 2014
  • Sak K., Everaus H. Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells Current Stem Cell Research & Therapy, 2014
  • Kase M., Adamson A., Saretok M., Minajeva A., Vardja M., Jõgi T., Asser T., Jaal J. Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme Journal of Neurosurgical Sciences, 2014

 

2013

  • Bennouna J., Sastre J., Arnold D., Osterlund P., Greil R., Van Cutsem E., von Moos R., Vieitez JM., Bouche O., Borg C., Steffens CC., Alonso-Orduna V., Schlichting C., Reyes-Rivera I., Bendahmane B., Andre T., Kubicka S., ML18147 Study Investigators.
    Autorite grupp: Elme A., Mägi A., Ojamaa K. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology: 14 (1), 29-37, 2013
  • Kubicka S., Greil R., Andre T., Bennouna J., Sastre J., Van Cutsem E., von Moos R., Osterlund P., Reyes-Rivera I., Müller T., Makrutzki M., Arnold D., ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, AGMT groups
    Autorite grupp:Elme A., Mägi A., Ojamaa K.  Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of Oncology: 24 (9), 2342-2349, 2013
  • Tjalma WA., Fiander A., Reich O., Powell N., Nowakowski AM., Kirschner B., Koiss R., O'Leary J., Joura EA., Rosenlund M., Colau B., Schledermann D., Kukk K., Damaskou V., Repanti M., Vladareanu R., Kolomiets L., Savicheva A., Shipitsyna E., Ordi J., Molijn A., Quint W., Raillard A., Rosillon D., De Souza SC., Jenkins D., Holl K., HERACLES/SCALE Study Group. Autorite grupp:Vaasna I., Oro S. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. International Journal of Cancer: 132 (4), 854-867, 2013
  • Štšerbakova A., Lust H., Everaus H., Aints A. A mathematical model of natural killer cell activity. Cytometry Part A: 83A (6), 585-591, 2013
  • Klewes L., Vallente R., Dupas E., Brand C., Grün D., Guffei A., Sathitruangsak C., Awe JA., Kuzyk A., Lichtensztejn D., Tammur P., Ilus T., Tamm A., Punab M., Rubinger M., Olujohungbe A., Mai S. Three-dimensional Nuclear Telomere Organization in Multiple Myeloma. Translational Oncology: 6 (6), 749-756, 2013
  • Raber-Durlacher JE., von Bültzingslöwen I., Logan RM., Bowen J., Al-Azri AR., Everaus H., Gerber E., Gomez JG., Pettersson BG., Soga Y., Spijkervet FK., Tissing WJ., Epstein JB., Elad S., Lalla RV., MASCC/ISOO. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer: 21 (1), 343-355, 2013
  • Punab M., Palk K., Varik M., Laane E., Everaus H., Holmberg E., Hulegardh E., Wennström L., Safai-Kutti S., Stockelberg D., Kutti J. Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982-2006: a survey of patients aged ≥65 years. Medical Oncology: 30 (1), Artikli nr 487, 2013
  • Innos K., Padrik P., Valvere V., Eelma E., Kütner R., Lehtsaar J., Tekkel M. Identifying women at risk for delayed presentation of breast cancer: a cross-sectional study in Estonia. BMC Public Health: 13, Artikkel nr 947, 2013
  • Kase M., Minajeva A., Niinepuu K., Kase S., Vardja M., Asser T., Jaal J. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme. Radiology and Oncology: 47 (4), 405-410, 2013.
  • Uusküla A., Raag M., Uppin A., Raud T., Klaar U., Jürisson M., Müürsepp A. Incidence of cervical intraepithelial neoplasia in Estonia. Journal of Lower Genital Tract Disease: 17 (2), 129-136, 2013
  • Jõgi T., Jaal J. Erialauudised. Onkoloogia. Eesti Arst: 92 (3), 166-166, 2013
  • Kallak K., Padrik P. Tõenduspõhine rinnavähi kiiritusravi. Eesti Arst: 92 (10), 575-580, 2013
  • Volke A., Erm T., Merisalu S., Hussar K.Akraalne melanoom. Eesti Arst: 92 (7), 397-397, 2013
  • Padrik P. Kommentaar artiklile "Taani ekspert: kvaliteedi hindamine on kliinilise töö osa". Eesti Arst: 92 (9), 495-495, 2013
  • nnos K., Baburin A., Valvere V., Aareleid T., Padrik P. Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage. European Journal of Cancer: 49 (Suppl 2), S304-S305, 2013
  • Ambagtsheer F., Noord M., Zuidema WC., Dor FJMF., Baan C., Ploeg RJ., Ponchia A., Parisotto C., Lennerling A., Loven C., Gutmann T., Fateh-Moghadam B., Dobbels F., Duerinckx N., Pascalev A., Ilieva A., Krastev Y., Sandor J., Besirevic V., Demeny E., Florea T., Codreanu N., Fleshtor C., Liivand R., Everaus H., Frunza M., Czerwinski J., Lewandowska D., Weimar W. EULOD – the EU-funded Project on Living Organ Donation in Europe. Transplant International: 26 (Suppl 2, SI), 139-140, 2013
  • Hoffmann VS., Lindoerfer D., Pfirrmann M., Saussele S., Hochhaus A., Engel J., Guilhot J., Rosti G., Mayer J., Indrak K., Castagnetti F., Turkina A., Zaritskey A., Steegmann JL., Hellmann A., Thielen N., Cervantes F., Simonsson B., Colita A., Clark RE., Almeida A., Labar B., Marin D., Ossenkoppele GJ., Bogdanovic A., Dyagil I., Porkka K., O'Brien S., Griškevičius L., Panagiotidis P., Thaler J., Zupan I., Lejniece S., Everaus H., Masszi T., Melanthiou F., Hehlmann R., Hasford J., Baccarani M. CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. Blood: 122 (21), Tees nr 2735, 2013
  • Dmitrieva N., Mikkel S., Kübarsepp V., Varik K. Occurrence of abdominal pain in the case of malignant abdominal tumours. 2nd Baltic Paediatric Congress, 30.05.-01.06.2013: 75-75, 2013
  • Mirka G., Mikkel S. Pediatric lymphomas. 2nd Baltic Paediatric Congress, 30.05.-01.06.2013: 79-79, 2013
  • Bozsaky E., Jaal J., Dörr W. Expression of uroplakin-III and occludin in irradiated mouse bladder urothelium. 40th Annual Meeting of the European Radiation Research Society, 1 -5 September 2013, Dublin, Ireland: Tees nr M-39, 2013
  • Lukjanova J., Metsaots T., Minajeva A., Joonsalu M., Jõgi T., Kase M., Adamson A., Saretok M., Vardja M., Asser T., Jaal J. Galektiin-1 ekspressioon multiformse glioblastoomi koes ning selle seos kasvajat infiltreerivate põletiku- ja immuunrakkudega. Eesti Arst: 92 (Lisa 2), 29-30, 2013
  • Metsaots T., Lukjanova J., Minajeva A., Joonsalu M., Kase M., Jõgi T., Vardja M., Asser T., Jaal J. DNA reparatsiooniensüümi DNA-PK ning somatostatiini retseptori ekspressioon multiformse glioblastoomi koes. Eesti Arst: 92 (Lisa 2), 14-14, 2013
  • Ojamaa K., Kase M., Jõgi T., Kütner J., Niinepuu K., Tammaru M., Mägi M., Jaal J. Alla 45aastaste isikute osakaal vähki haigestunute hulgas enam levinud paikmete kaupa Eestis aastatel 1980–2008. Eesti Arst: 92 (Lisa 2), 11-11, 2013
  • Tammik I., Vaasna O. Radical abdominal trachelectomy – safe method for early cervical cancer treatment. The International Congress on Oncological Perspectives of Fertility Preservation: Gynecological & Breast Cancer, 21.03–23.03.2013, Berlin, Germany, 2013
  • Võrno T., Kuusemäe K., Valvere V., Padrik P., Ulp S., Pisarev H., Zegulova A., Puusepp M., Lippus H., Kiivet RA. Mammograafia rinnavähi sõeluuringus: tervisetehnoloogia hindamise raport TTH05. Mammograafia rinnavähi sõeluuringus: tervisetehnoloogia hindamise raport TTH05: 1-80, 2013
  • Padrik P., Everaus H. Onkoloogia õpik. Tartu Ülikooli Kirjastus, 2013

  

2012

  • Kasari, Marje; Padrik, Peeter; Vaasa, Angela; Saar, Kristi; Leppik, Krista; Soplepmann, Jaan; Uri, Asko (2012). Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers. Analytical Biochemistry, 422(2), 79 – 88, artikkel 1.1
  • Vrdoljak, E.; Ciuleanu, T.; Kharkevich, G.; Mardiak, J.; Mego, M.; Padrik, P.; Petruželka, L.; Purkalne, G.; Shparyk, Y.; Skrbinc, B.; Szczylik, C.; Torday, L. (2012). Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opinion on Pharmacotherapy, 13(2), 159 – 174, artikkel 1.1
  • Mieog, J.; Morden, J.; Bliss, J.; Coombes, R.; van de Velde, C.; Intergroup Investigators, inc. Padrik, P. (2012). Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. The Lancet Oncology, 13(4), 420 – 432, artikkel 1.1
  • Jaal, J.; Putnik, K. (2012). Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin. Acta Oncologica, 51(7), 952 – 954, artikkel 1.1
  • Crocetti, Emanuele; Trama, Annalisa; Stiller, Charles; Caldarella, Adele; Soffietti, Riccardo; Jaal, Jana; Weber, Damien; Ricardii, Umberto; Slowinski, Jerzy; Brandes, Alba and the RARECARE working group. (2012). Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 48(10), 1532 – 1542, artikkel 1.1
  • Siesling, S.; Zwan, JM.; Izarzugaza, I.; Jaal, J.; Treasure, T.; Foschi, R.; Ricardi, U.; Groen, H.; Tavilla, A.; Ardanaz, E. (2012). Rare thoracic cancers, including peritoneum mesothelioma. European Journal of Cancer, 48(7), 949 – 960, artikkel 1.1
  • Konovalova, O.; Jaal, J. (2012). Vähiravist põhjustatud kardiotoksilisus. Eesti Arst, 91(2), 84 – 92, artikkel 1.3
  • Innos, Kaire; Soplepmann, Jaan; Suuroja, Tiit; Melnik, Priit; Aareleid, Tiiu (2012). Survival for colon and rectal cancer in Estonia: Role of staging and treatment. Acta Oncologica, 51(4), 521 – 527, artikkel 1.1
  • Kasari, Marje; Padrik, Peeter; Vaasa, Angela; Saar, Kristi; Leppik, Krista; Soplepmann, Jaan; Uri, Asko (2012). Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers. Analytical Biochemistry, 422(2), 79 – 88, artikkel 1.1
  • Puurand, M.; Peet, N.; Piirsoo, A.; Peetsalu, M.; Soplepmann, J.; Sirotkina, M.; Peetsalu, A.; Hemminki, A.; Seppet, E. (2012). Deficiency of the complex I of the mitochondrial respiratory chain but improved adenylate control over succinate-dependent respiration are human gastric cancer-specific phenomena. Molecular and Cellular Biochemistry, x, artikkel 1.1
  • Mikita, Valdur; Joost, Kairit; Laidre, Piret; Toome, Kadri; Tõnisson, Neeme; Soplepmann, Jaan; Rebane, Egle; Kostina, Olga; Roomere, Hanno (2012). Päriliku jämesoolevähiga patsientide geneetilise konsulteerimise ja jälgimise juhend. Eesti Arst, 269 – 275, artikkel 1.3
  • Rahu, Marge; Hein, Marju, Everaus, Hele (2012). Clinical Presentation, Treatment and Outcome in HIV-infected Patients with Hematological Malignancies Treated at Tartu University Hospital. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 73 - 74, konverentsi teesid 5.2
  • Mikkel, Sirje; Päärson, Karit; Everaus, Hele (2012). Gaucher Disease - Underdiagnosed Cause of Thrombocytopenia and Splenomegaly. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 68 – 69, konverentsi teesid 5.2
  • Lehtmaa, Jane; Telling, Siiri; Kaare, Ain; Everaus, Hele (2012). The Incidence of Graft-Versus-Host Disease After Allogeneic Transplantation. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 66 - 67, konverentsi teesid 5.2
  • Laane, Edward; Varik, Mirja; Loigom, Diana; Everaus, Hele; Punab, Mari (2012). Efficacy of the First Line Imatinib Treatment of CP-CML in Estonia. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 65, konverentsi teesid 5.2
  • Kaare, Ain; Telling, Siiri; Everaus, Hele (2012). Allogeneic Hemopoietic Stem Cell Transplantation in Estonia. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 56 - 57, konverentsi teesid 5.2.
  • Laane, Edward; Björklund, Elisabet; Mazur, Joanna; Everaus, Hele; Kirsimägi, Ülle; Lönnerholm, Gunnar; Söderhäll, Stefan; Porwit, Anna (2012). Dendritic Cell Regeneration in Children Treated for Acute Lymphoblastic Leukemia by Nopho All-2000 Protocol. In: Abstract book 8th Baltic Conference on Hematology : 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 54, konverentsi teesid 5.2
  • Punab, Mari; Varik, Mirja; Palk, Katrin; Everaus, Hele; Laane, Edward; Kutti, Jack (2012). Epidemiologic Study on Acute De Novo Leukaemias in Estonia and in a Well-Defined Region of Western Sweden. In: Abstract book 8th Baltic Conference on Hematology : 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 42 - 43, konverentsi teesid 5.2
  • Everaus, Hele (2012). Gaucher Disease - Problems in Diagnostics and Current Treatment Options. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 30, konverentsi teesid 5.2
  • Everaus, Hele (2012). Hematology - Where we are and Future Opportunities. In: Abstract book 8th Baltic Conference on Hematology: 8th Baltic Conference of Hematology, 12.-14.04.2012, Tallinn. , 2012, 24, konverentsi teesid 5.2
  • Mikkel, S.; Boriskina, K.; Talvik, I.; Reimand, T.; Everaus, H. (2012). Familiar hemophagocytic lymphohistiocytosis - case report . In: Abstract book 8th Baltic Conference on Hematology : 8th Baltic Conference on Hematology; 12-14.04.2012; Tallinn. , 2012, 77 - 78, konverentsi teesid 5.2
  • Kase, M.; Vardja, M.; Niinepuu, K.; Kase, S.; Minajeva, A.; Asser, T.; Jaal, J. (2012). Stem cells may not contribute to radioresistance of glioblastoma multiforme. In: Radiotherapy and Oncology: ESTRO 31, 09.-13.05.12, Barcelona, Spain. Elsevier, 2012, (103, suppl 1), S88, konverentsi teesid 5.1
  • Asser T, Kase M, Vardja M, Niinepuu K, Kase S, Minajeva A, Jaal J. (2012). Impact of stem cells on survival in patients with glioblastoma multiforme. 12th Congress of the Baltic Neurosururgical Association 18-20.05.2012, Riga. , 2012, konverentsi teesid 5.2
  • Saar, M.; Jaal, J.; Johnson, B.J. (2012). Identifing the need of community pharmacists for a specialised educational programme to support patients receiving oral chemotherapy in Estonia. In: Eur J Oncol Pharm:, 2012, (6), 55, konverentsi teesid 5.2
  • Kase, M.; Minajeva, A.; Kase, S.; Niinepuu, K.; Vardja, M.; Asser, T.; Jaal, J. (2012). Three WWW questions about glioblastoma multiforme: WHEN is the right time for cancer stem cell targeting? In: Eesti Arst: TÜ arstiteaduskonna aastapäeva teaduskonverents, Tartu, 11.10.12-12.10.12. , 2012, (Lisa 1), 29, konverentsi teesid 5.2
  • Adamson, A.; Saretok, M.; Kase, M.; Minajeva, A.; Vardja, M.; Asser, T.; Jaal, J. (2012). Three WWW questions about glioblastoma multiforme: WHAT is the role of inflammation? In: Eesti Arst: TÜ arstiteaduskonna aastapäeva teaduskonverents, Tartu, 11.10.12-12.10.12. , 2012, (Lisa 1), 17, konverentsi teesid 5.2
  • Saretok, M.; Adamson, A.; Kase, M.; Minajeva, A.; Kase, S.; Niinepuu, K.; Vardja, M.; Asser, T.; Jaal, J. (2012). Three WWW questions about glioblastoma multiforme: WHICH type of tumour blood vessel formation to inhibit? In: Eesti Arst: TÜ arstiteaduskonna aastapäeva teaduskonverents, Tartu, 11.10.12-12.10.12. , 2012, (Lisa 1), 16, konverentsi teesid 5.2
  • Kase, M.; Minajeva, A.; Niinepuu, K.; Kase, S.; Adamson, A.; Saretok, M.; Vardja, M.; Asser, T.; Jaal, T. (2012). Blood vessels with different characteristics have distinct impact on survival of glioblastoma multiforme patients. In: Annals of Oncology: ESMO37; Vienna, Austria; 28.09.12-02.10.12. , 2012, (vol 23, suppl 9), abs 431, konverentsi teesid 5.2
  • Jaal, J.; Kase, M.; Minajeva, A.; Niinepuu, K.; Kase, S.; Vardja, M.; Asser, T. (2012). Association between cancer stem cells and CD133+ blood vessels in glioblastoma multiforme. In: Annals of Oncology: ESMO37; Vienna, Austria; 28.09.12-02.10.12. , 2012, (vol 23, suppl 9), 418PD, konverentsi teesid 5.2
  • Kask, M.; Toome, K.; Jaal, J.; Soplepmann, J.; Afanasjev, V.; Laidre, P.; Erm, T.; Raime, K.; Vaidla, K.; Roomere, H. (2012). Genetic Screening of Colorectal Cancer Patients to Detect Hereditary Colorectal Cancer Syndromes in Estonian Population. European Human Genetics Conference, June 23-26,2012. NCC Ost; Nürnberg, Germany; Abstracts. P06.067.. , 2012, konverentsi teesid 5.2
  • Kask, M.; Toome, K.; Jaal, J.; Soplepmann, J.; Afanasjev, V.; Laidre, P.; Erm, T.; Raime, K.; Vaidla, K.; Roomere, H. (2012). Genetic Screening of Colorectal Cancer Patients to Detect Hereditary Colorectal Cancer Syndromes in Estonian Population. European Human Genetics Conference, June 23-26,2012. NCC Ost; Nürnberg, Germany; Abstracts. P06.067.. , 2012, konverentsi teesid 5.2
  • Soplepmann, Pille; Uppin, Arno; Soplepmann, Jaan (2012). Results of Wertheim`s operation combined with formation of a neovagina using sigmoid colon segment. Case report. EBCOG, 9-12 May 2012, Tallinn, Estonia. The Book of Abstracts. P05.02.. , 2012, konverentsi teesid 5.2 
  • Altmets, Mait; Altraja, Alan; Ambos, Anu; Andresen, Kadri; Arumäe, Katrin; Brachinsky, Mark; Elmet, Märt; Haldre, Sulev; Hedman, Anu; Kahu, Jaanus; Kaljusaar, Heli; Kallikorm, Riina; Karelson, Maire; Karjagin, Juri; Kaur, Sirje; Kingo, Külli; Koorits, Ursula; Kull, Karin; Kõrv, Janika; Linnamägi, Ülla; Maasalu, Katre; Muda, Piibe; Mülle, Helen; Otter, Karin; Padrik, Peeter; Rajasalu, Tarvo; Rosenberg, Mai; Saadla, Peeter; Saks, Kai; Silm, Helgi; Starkopf, Joel; Sukles, Kai; Taba, Pille; Teesalu, Rein; Timberg, Gennadi; Uuetoa, Hasso; Uuetoa, Tiina (2012). Eakate farmakoteraapia. Tallinn: Medicina, teadusväljaannete toimetamine 4.2

 

2011

 

  • Wennström L., Safai-Kutti S., Stockelberg D., Holmberg E., Palk K., Varik M., Viigimaa I., Vaht K., Luik E., Everaus H., Kutti J. (2011) The Incidence and Survival of Acute de novo Leukemias in Estonia and in a Well-Defined Region of Western Sweden during 1997-2001: A Survey of Patients Aged 16-64 Years. Acta Haematol 2011;126:176-185, artikkel 1.1.
  • Kase, M.; Vardja, M.; Lipping, A.; Asser, T.; Jaal, J. (2011). Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme. Radiotherapy and Oncology: 101 (1), 127-131, 2011. artikkel 1.1.

  • Aareleid T., Gondos A., Brenner H., Pokker H., Leppik K., Mägi M. (2011) Testicular cancer survival in Estonia: Improving but still relatively low Acta Oncologica: 50 (1), 99-105, 2011. artikkel 1.1.

  • Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu MC., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay MA., Riva A., Crown J., Breast Cancer International Research Group. Autorite grupp:Padrik P., Valvere V. (2011)  Adjuvant Trastuzumab in HER2-Positive Breast Cancer New England Journal of Medicine: 365 (14), 1273-1283, 2011. artikkel 1.1.

  • Smith, I.; Pierga, J.; Biganzoli, L.; Cortés-Funes, H.; Thomssen, C.; Pivot, X.; Fabi, A.; Xu, B.; Stroyakovskiy, D.; Franke, F.; Kaufman, B.; Mainwaring, P.; Pienkowski, T.; De Valk, B.; Kwong, A.; González-Trujillo, JL.; Koza, I.; Petrakova, K.; Pereira, D.; Pritchard, K; ATHENA Study Group incl. Padrik, P. (2011). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Annals of Oncology, 22(3), 595 - 602. artikkel 1.1.

  •  Anderson, Kristina; Lutz, Christoph; Van Delft, Frederik; Bateman, Caroline; Guo, Yanping; Colman, Susan; Kempski, Helena; Moorman, Anthony; Titley, Ian; Swansbury, John; Kearney, Lyndal; Enver, Tariq; Greaves, Mel. (2011). Genetic variegation of clonal architecture and stem cells in leukemia. Nature, 469(469), 356 - 361. artikkel 1.1.

  • van Delft, Frederic; Horsley, Sharon; Colman, Susan; Anderson, Kristina; Bateman, Caroline; Kempski, Helena; Zuna, Jan; Eckert, Cornelia; Saha, Vaskar; Kearney, Lyndal; Ford, Anthony; Greaves, Mel. (2011). Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood, 117(23), 6247 - 6254. artikkel 1.1.

  •  Buentke, E.; Nordström, A.; Lin, H.; Björklund, A.C.; Laane, E.; Harada, M.; Lu, L.; Tegnebratt, T.; Stone-Elander, S.; Heyman, M.; Söderhäll, S.; Porwit, A.; Östenson, C.G.; Shoshan, M.; Pokrovskaja Tamm, K.;Grandér, D. (2011). Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer Journal, 1(July), 1 - 9. artikkel 1.1.

  •  Innos K., Soplepmann J., Suuroja T., Melnik P., Aareleid T. (2011) Survival for colon and rectal cancer in Estonia: Role of staging and treatment Acta Oncologica, 2011, artikkel trükimenetlusel

  •  Padrik, P. (2011). Metastaatilise neeruvähi uued ravivõimalused . Eesti Arst, 90(1), 35 - 40. artikkel 1.3.

  •  Jaal, J. (2011). Madaladoosilisel kompuutertomograafial rajanev sõeluuring vähendab suremust kopsuvähki. Eesti Arst, 90(8), 386. artikkel 1.3.  

  • Jaal, J. (2011). Pea ja kaelapiirkonna kasvajate kiirendatud kiiritusravi on efektiivsem. Eesti Arst, 90(1), 41, artikkel 1.3.

  • Reima H., Saar H., Soplepmann J. (2011) Kolorektaalse kartsinoomi operatsioonipreparaatide ex vivo värvimine metüleensinisega lümfi - sõlmede tuvastamise parandamiseks Eesti Arst: 90 (9), 406-410, 2011. artikkel 1.3.

  • Ulst K., Eelma E. (2011) Melanoomihaige järelkontrollil 18F-FDG-PET-KT uuringul juhuleiuna avastatud primaarne rinnavähk Eesti Arst: 90 (8), 380-381, 2011. artikkel 1.3.

  • S. Telling, G. Raieste, M. Mõtus, K. Jugar, G. Kõks, A. Kaare, H. Everaus. (2011) Our story – the past and present of bone marrow transplantation nursing in Tartu University Hospital, Estonia, 02.04-06.04.2011 Pariis, Prantsusmaa. konverentsi teesid 5.1.

  • Vorobjova T., Kull K., Saar H., Labotkin R., Zimmermann A., Maaroos H. (2011) Atrophic gastritis by the OLGA stages and Helicobacter CagA seropositivity in gastric canser Helicobacter: 16 (SI, Suppl 1), 79-79, 2011 konverentsi teesid 5.1.

  • Hasford J., Almedia A., Baccarani M., Bogdanovic A., Clark R., Colita A., Costeas P., Demeckova E., Dyagil I., Everaus H., Griskevicius L., Guilhot J., Hehlmann R., Hellmann A., Hoffmann V., Indrak K., Koskenvesa P., Labar B., Lejniece S., Lindoerfer D., Ossenkoppele G., Panagiotidis P., Rosti G., Simonsson B., Steegmann J., Thaler J., Turkina A., Zackova D., Zaritskey A., Zupan I. (2011) The European Population-based CML Registry. Obejctives and First Results. konverentsi teesid 5.2 

  • Everaus, H. (2011). Ethical Aspects of Personalized Medicine. In: EPMA Journal : The EPMA World Congress, World Congress on Predictive, Preventive & Personalised Medicine (PPPM), Bonn, Germany, 15-18 September 2011. Springer, 2011, (2 (Suppl 1)), S192. konverentsi teesid 5.2

  • Everaus H. (2011) Closer to personalized approach through accepting the gender differencies in chronic lympocytic leukaemia (CLL) 15.-23.08.2011, Havai. konverentsi teesid 5.2

  •  Pihlak, R.; Trelin, O.; Neissar, H.; Kooleht, K.; Peterson, I.; Kivistik, S.; Lilo, K.; Järveots, M.; Jaal, J. (2011). Complementary and alternative medicine use among cancer patients receiving radiotherapy and chemotherapy. In: European Journal of Cancer: The European Multidisciplinary Cancer Congress, Stockholm 23-27 September, 2011. Elsevier, 2011, (Suppl. 1), S298. konverentsi teesid 5.2.

  • Pihlak, R.; Liivand, R.; Trelin, O.; Neissar, H.; Peterson, I.; Kivistik, S.; Lilo, K.; Järveots, M.; Jaal, J. (2011). Alternatiivmeditsiini kasutamine kasvajavastase kiiritus- ja keemiaravi jooksul. In: Eesti Arst: Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2011; Tartu, 13.10.11-14.10.11. Eesti Arst, 2011, (Lisa 1), 24. konverentsi teesid 5.2.

  • Jaal, J. (2011). Glioomide esinemissagedus ning glioomidega haigete elulemus ei ole Euroopa erinevates regioonides sarnane. In: Eesti Arst: Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2011; Tartu, 13.10.11-14.10.11. Eesti Arst, 2011, (Lisa 1), 17. konverentsi teesid 5.2.

  • Kase, M.; Vardja, M.; Lipping, A.; Asser, T.; Jaal, J. (2011). Impact of DNA repair enzymes on survival in patients with glioblastoma multiforme. In: Eesti Arst: Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2011; Tartu, 13.10.11-14.10.11. Eesti Arst, 2011, (Lisa 1), 10. konverentsi teesid 5.2.

  • Kase, M.; Vardja, M.; Lipping, A.; Asser, T.; Jaal, J. (2011). Impact of PARP and DNA-PK expression on survival in patients with glioblastoma multiforme. In: 12th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology: 12th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology; June 25-27, 2011; Ermatingen, Switzerland. (Toim.) Baumann, M.l; Bodis, S.; Dikomey, E.; van der Kogel, A.; Overgaard, J.; Rodeman, H.P., 2011, 75. konverentsi teesid 5.2.

  • Jaal, J. (2011). Kiiritusravist ja medikamentoossest ravist tingitud kopsukahjustus. In: Eesti Arstide Päevad: Eesti Arstide Päevad; Tallinn, Eesti; 17.-18.03.11. , 2011, 14. konverentsi teesid 5.2.

  • Jaal, J. (2011). Patsienti kui tervikut nähes. ABC Konverents 2010 ettekannete teesid. konverentsi teesid 5.2.

  • Niinepuu, K.; Minajeva, A.; Kase, M.; Vardja, M.; Jaal, J. (2011). Multiformse glioblastoomi CD133+ rakkude suurem osakaal ei seostu kasvaja agressiivsusega. Tartu Ülikooli arstiteaduskonna aastapäeva teaduskonverents 2011; Tartu, 13.10.11-14.10.11. Eesti Arst, 2011, (Lisa 1), 57. konverentsi teesid 5.2.

  • Tammik O., Vaasna I. (2011) Radical Abdominal Trachelectomy, Estonian experience International Journal of Gynecological Cancer: 21 (Suppl 3), 2011 konverentsi teesid 5.2.

  • Kordemets, T., Suija, K., Pechter, Ü., Kalda, R., Maaroos, HI. (2011) Patsientide kehaline aktiivsus ja nõustamine liikumisharjumuse suhtes peremeditsiinis. Eesti Arst: 90 (Lisa 1), 25-25, 2011, konverentsi teesid 5.2.

  • Punab, M. (2011) Aneemiate käsitlus. Eesti Arstide Päevad 2011: 8-8, 2011, konverentsi teesid 5.2.

  • Vainumäe I., Rägo T., Metsvaht T., Mikkel S., Vals MA., Talvik I., Luts K., Kahre T. (2011) Wilson disease in children in 1996-2009. Case reports Vaiku Pulmonologija ir Alergologija: 14 (1), 92-92, 2011 konverentsi teesid 5.2.

     

2010

  • Palk K., Luik E., Varik M., Viigimaa I., Vaht K., Everaus H., Wennström L., Stockelberg D., Safai-Kutti S., Holmberg E., Kutti J. The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997-2001: A survey of patients aged >/=65 years. Cancer epidemiology: 34 (1), 24-28, 2010, artikkel 1.1.    
  • Douroudis K., Štšerbakova A., Everaus H., Aints A. PTPN22 gene regulates natural killer cell proliferation during in vitro expansion. Tissue Antigens: 76 (4), 315-318, 201, artikkel 1.1.
  • Tamboom K., Kaasik K., Arsavskaja J., Tekkel M., Lilleorg A., Padrik P., Metspalu A., Veidebaum T. BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hereditary cancer in clinical practice: 8 (Article Number: 4), 7 lk., 2010, artikkel 1.1.
  • Padrik P., Saar H.    Thymidine phosphorylase as a prognostic factor in renal cell carcinoma. International urology and nephrology: 42 (2), 295-298, 2010, artikkel 1.1.   
  • Tehranchi R.; Woll PS.; Anderson K.; Buza-Vidas N.; Mizukami T.; Mead AJ.; Åstrand-Grundström I.; Strömbeck B.; Horvat A.; Ferry H.; Singh Dhanda R.; Hast R.; Rydén T.; Vyas P.; Göhring G.; Schlegelberger B.; Johansson B.; Hellström-Lindberg E.; List A.; Nilsson L.; and Jacobsen SEW. Persistent malignant stem cells in del(5q) myelodysplasia in remission. New England Journal of Medicine, 363, 1025 - 1037.2010, artikkel 1.1
  • Jaal J., Richter C., Dörr W. Effect of recombinant human keratinocyte growth factor (Delta23rHuKGF, Palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation. International Journal of Radiation Biology, 10 – 15, 2010, artikkel 1.1
  • Jaal J., Dörr W.    Radiation effects on cellularity, proliferation and EGFR expression in mouse bladder urothelium. Radiation Research: 173 (4), 479-85, 2010, artikkel  1.1.
  • Ilves P., Lintrop M., Talvik I., Sisko A., Talvik Ti. Predictive value of clinical and radiological findings in inflicted traumatic brain injury. Acta Paediatrica, 99(9), 1329 - 1336. 2010, artikkel 1.1
  • Laugesaar R., Kolk A., Uustalu Ü., Ilves P., Tomberg T., Talvik I., Köbas K., Sander V., Talvik T. Epidemiology of childhood stroke in Estonia. Pediatric Neurology, 42(2), 93 - 100. 2010, artikkel 1.1   
  • Everaus H.   VII Balti hematoloogiakonverents. Eesti Arst: 89 (7-8), 522-523, 2010, artikkel 1.3
  • Everaus H. Perearst –olulise rolliga kasvajate diagnostikas ja ravis? Perearst: 2010:9-11, artikkel 1.3. 
  • Jaal J. Metastaatilise kopsuvähi ravi Eesti Arst: 89 (Lisa 2), 79-87, 2010, artikkel 1.3.  

  • Jaal J., Kase M. Lokaalselt ja regionaalselt levinud kopsuvähi ravi Eesti Arst: 89 (Lisa 2), 68-77, 2010, artikkel 1.3.  

  • Jaal J., Mägi M. Viimaste aastakümnete suundumused kopsuvähi epidemioloogias Eesti Arst: 89 (Lisa 2), 5-11, 2010, artikkel 1.3.  

  • Kase M., Laisaar T., Jaal J. Kopsuvähist tingitud aju- ja luumetastaasid ning pleuraefusioon Eesti Arst: 89 (Lisa 2), 88-96, 2010, artikkel 1.3.  

  • Kullamaa A., Jaal J. Suitsetamise roll kopsuvähi tekkes ja edasises haiguskulus Eesti Arst: 89 (Lisa 2), 12-17, 2010, artikkel 1.3. 

  • Lintrop M., Talvik I., Tolpats V., Nellis G., Mikkel S., Padari H., Napa A., Ilves P. Posterioorse reversiibelse entsefalopaatia sündroom (PRES): kirjanduse ülevaade ja kahe haigusjuhu kirjeldus. Eesti Arst: 89 (3), 191-199, 2010, artikkel 1.3.
  • Everaus H. Sterility, Infertility and Teratogenicity. The MASCC Textbook of Cancer Supportive Care and Survivorship, Spinger 2010. Edited I.N Olver, peatükk raamatus 3.1
  • Everaus H. Bioeetikast biomeditsiinilise eetikani. Usaldus. Eesti ja maailm. Metsaülikool Eestis 2008-2009 (x - x).Hardman, 2010, artikkel 3.2
  • Wachowiak J., Afanasyev B., Aleinikova O., Colita D., Gozdzik J., Kaare A., Kalman N., Kowalczyk J., Lange A., Pretnar J., Rascon J., Sulfiarska S., Vujic D., Wysocki M., Peters C. Needs of paediatric haematopoietic stem cell transplant centres in Eastern Europe - the EBMT Paediatric Diseases Working Party Survey.  Bone marrow transplantation: 45 (Suppl. 2), S265-S265, 2010, konverentsi teesid 5.1.   
  • Everaus H. Personalized medicine – dream or reality? 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Douroudis K., Shcherbakova A., Everaus H., Aints A. PTPN22 Gene regulates NK cell proliferation during in vitro expansion. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Hein M., Rõivassepp K., Everaus H. Outpatient primary visits to hematologist in Tartu – an overview of one year period. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Lehtmaa J., Kaare A., Everaus H. Unusual infectious complications after autologous peripheral blood stem cell transplantion. Case report. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Anderson K. Genetic variegation of clonal architecture and stem cells in childhood acute lymphoblastic leukaemia. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Laane E. Dexamethasone, lymhoplast and autophagy. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Kaare A. Allogeneic haematopoietic stem cell transplantation in acute leukemias: one centre experience. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Mikkel S. Quality of life after stem cell transplantation in Estonia. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Punab M., Varik M. Current situation in treatment of chronic myeloid leukaemia in Estonia. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Zolotova O., Luppova N. Summer days with hemophilia patients in Estonia. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Telling S. Review of side effects during peripheral stem cell apheresis and nursing management of side effects. 7th Baltic Conference of Hematology, 20-22 May, 2010, konverentsi teesid 5.2
  • Jaal J., Torm T., Everaus H. Palliative chemotherapy: the role of natural killer cells and interleukin-6. In: abstract book: 5th Baltic Congress of Oncology, Riga, Latvia, May 14-15. , 2010, 67 - 68., konverentsi teesid 5.2
  • Jaal J. Seljaaju ja ülemise õõnesveeni kompressiooni sündroom Eesti Arstide Päevad 2010: 13-14, 2010, konverentsi teesid 5.2.

  • Štserbakova A., Douroudis K., Everaus H., Aints A. PTPN22 regulerib NK- ja T-rakkude suhet in vitro ekspansiooni käigus. Eesti Arst: 89 (9), 579, 2010, konverentsi teesid 5.2.    
  • Vainumäe I., Rägo T., Metsvaht T., Mikkel S., Talvik I., Vals MA., Luts K., Kahre T. Wilsoni tõbi lastel. 1996–2009 TÜ Kliinikumi lastekliinikus diagnoositud juhud.    Eesti Arst: 89 (Lisa1), 62, 2010, konverentsi teesid 5.2.    
  • Vals MA., Mikkel S., Lintrop M., Salumäe L., Talvik I. Aju aspergilloom. Eesti Arst: 89 (Lisa1), 40, 2010, konverentsi teesid 5.2.
  • Lintrop, M.; Tamm, A.E.; Ilves, P.; Tamm, A.O. Synovial vascularity in early knee osteoarthritis assessed by quantitative contrast-enhanced and power Doppler ultrasound. The 3rd Baltic Congress of Radiology; Riga, Latvia; October 8-9th, 2010, konverentsi teesid 5.2
  • Ilves P., Lintrop M., Talvik I., Sisko A. Correlations between late radiological findings and long-term neurodevelopmental outcome in inflicted traumatic brain injury. In: Pediatric Radiology: ESPR 2010; Bordeaux, France; 7-10 June 2010. Springer, 2010, 1076, konverentsi teesid 5.2 
  • Lintrop M., Ilves Pi., Tolpats Vi., Talvik I. Posterior reversible encephalopathy syndrome: two cases in children. In: Pediatric Radiology: ESPR 2010; Bordeaux, France; 7-10 June. Springer, 2010, 1116, konverentsi teesid 5.2
  • Lintrop M., Tamm A., Murde M., Pintsaar Ai., Rips L., Kukner A., Tein T., Saluse T., Märtson A., Ilves P., Tamm A.  Synovial vascularity in early knee osteoarthritis assessed by quantitative contrast-enhanced ultrasound, power Doppler ultrasound and arthroscopic biopsy. In: Osteoarthritis and Cartilage: The 2010 World Congress on Osteoarthritis; Bryssels, Belgium; Sept 23-26, 2010. (Toim.) Lohmander, S. Elsevier, 2010, (Supplement 2), 519 – 520, konverentsi teesid 5.2   

2009

  • Kenemans P., Bundred NJ., Foidart JM., Kubista E. et al.; LIBERATE Study Group: Padrik P.  Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial  The lancet oncology 2009, 10 (2): 135-146  artikkel  1.1.
  • Jaal J., Dörr W.  Radiation effects on cellularity, proliferation and EGFR expression in mouse bladder urothelium  Radiation Research 2009,  artikkel 1.1.
  • Palk K., Luik E., Varik M., Viigimaa I., Vaht K., Everaus H., Wennström., The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997 -  2001. Cancer epidemiology, 34 (1): 24-28 artikkel 1.2.
  • Padrik P., Saar H.  Thymidine phosphorylase as a prognostic factor in renal cell carcinoma  International urology and nephrology [Epub ahead of print] 2009,  artikkel 1.2.
  • Suija K.  Vähihaigete koduse toetusravi 12 aasta kogemus Eestis  Eesti Arst 2009, 88 (10): 682-685  artikkel  1.3.
  • Jaal J.  Radiokemoteraapia bioloogilised alused ja kliinilised näidustused  Eesti Arst 2009, 88 (10): 641-647  artikkel  1.3.
  • Altuhhova D., Makko H., Jaal J.  Mitteväikerakulise kopsuvähi kombineeritud ravi  Eesti Arst 2009, 88 (10): 669-675  artikkel  1.3.
  • Jaal J., Liivat K.  Vähivastasest kiiritus- ja keemiaravist tingitud kõhulahtisus  Eesti Arst 2009, 88 (12): 821-829  artikkel  1.3.
  • Shcherbakova A., Douroudis K., Everaus H., Aints A.  PTPN22 regulates NK/T cell ratio during in vitro expansion  HUMAN GENE THERAPY 2009, 20 (11): 1420-1421  konverentsi teesid  5.1.
  • Bystricka E., Vokurka S., Brandejsova R., Viirsalu V., Telling S.  Current protective isolation policy within East, Middle and West European transplant centres - A pilot survey  Bone marrow transplantation 2009, 43 (Supplement: Suppl. 1): S329-S330  konverentsi teesid 5.1.
  • Schellekens J., Stserbakova A., Wieten L., Tons M., Everaus H., Tilanus MGJ., Aints A.,  HLA influence on NK cell expansion  Tissue antigens 2009, 73 (5): 396-397  konverentsi teesid 5.1.
  • Jaal, J., Richter, C., Doerr, W. Effect of Recombinant Human Keratinocyte Growth Factor (rHuKGF, Palifermin) on inflammatory changes in mouse tongue during fractionated irradiation. In: Molecular Radiation Biology Oncology: proceedings of 11th Wolfsberg Meeting on Molecular Radiation Biology Oncology, 8: 71 (ISBN 3-9808819-5-4). konverentsi teesid 5.2.
  • Pierga J., Pritchard KI., Thomssen C., Cortes-Funes H., Biganzoli L., Padrik P., Zvirbule Z., Smith I.  Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT  Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings 2009, 27 (15S): Abstract 1033  konverentsi teesid 5.2.
  • Townsend AR., Millward M., Price T., Mainwaring P., Spencer A., Longenecker A., Palladino MA., Lloyd GK., Spear MA., Padrik P.  Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).  Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009, 27 (15S): Abstract 3582  konverentsi teesid 5.2.
  • Spencer A., Millward M., Mainwaring P., Padrik P.  Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052  Blood (ASH Annual Meeting Abstracts) 2009, 114 (22): Abstract 2693  konverentsi teesid 5.2.
  • Haviko T., Järveots M.  Assessment of the quality of life and coping of coxarthrosis patients before and six months after hip arthroplasty  10th EFORT Congress Vienna 2009 2009, P352  konverentsi teesid 5.2.
  • Suija K., Suija K.  Speciality of doctors working in palliative home care in Estonia  European Journal of Palliative Care: 11th Congress of the European Association for Palliative Care, 7th-10th May 2009, S267  konverentsi teesid 5.2.
  • Everaus H.  Märksõnaartiklid.  Tervise ABC 2009,  peatükk raamatust  6.1.
  • Everaus H.  Bioeetikast biomeditsiinilise eetikani. Eesti Päevaleht 2009, (30): 10,11  artikkel  6.3.
  • Everaus H.  Erialaseltsi ülevaade: Eesti Hematoloogide Selts. Lege Artis 2009, (2(81)): 37  artikkel  6.3.
  • Jaal J.  Retroperitoneaalsete tuumorite diferentsiaaldiagnostika. Lege Artis 2009, (3(82)): 10-12  artikkel  6.3.

2008

  • Štšerbakova A., Everaus H., Aints A. Loomulike tappurrakkude aktiivsuse tsütomeetrillne määramine. Eesti Arst 2008, 87 (10): 738-747, artikkel 1.3
  • Kuum T., Ilves P., Ulp S., Tammik O. Pankreasevähi operatsioonieelne kompuutertomograafiline diagnostika. Eesti Arst 2008, 87 (10): 763-767, artikkel 1.3.
  • Talvik I., Ilmoja ML., Jaanimägi T., Lintrop M., Mikkel S., Padari H., Toome L., Talvik T. Vastsündinute hiline hemorraagiline tõbi ehk hiline K-vitamiini defitsiidist põhjustatud verejooks. Kirjanduse ülevaade ja haigusjuhu kirjeldus. Eesti Arst 2008, 87 (10): 812-819, artikkel 1.3.
  • Grünberg H., Mikkel S. Aneemia lapseeas. Eesti Arst 2008, 87 (12): 962-967, artikkel 1.3.
  • Suija K., Suija K. Palliatiivne ravi: printsiibid ja eesmärgid. Eesti Arst 2008, 87 (3): 205-209 artikkel 1.3.
  • Jaal, J. Vähk ja Vitamiinid. Apteeker 1, 11-13 artikkel
  • Padrik P., Price TJ., Spear MA ., Townsend A., Longenecker A., Palladino MA., Lloyd KG., Cropp GF., Millward M.Phase 1 study of the novel proteasome inhibitor NPI-0052 in patients with advanced malignancies including leukemias. Annals of oncology 2008, 19 (Supplement: Suppl. 8 ): 162-162, konverentsi teesid 5.1.
  • Aints A., Schellekens J., Stserbakova A., Tons M., Everaus H., Tilanus M. NK cell expansion is dependent on genotype. Cellular oncology 2008, 30 (2): 178-178, konverentsi teesid 5.1.
  • Townsend A., Padrik P., Mainwaring P. Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D. EJC SUPPLEMENTS 2008, 6 (12): 74-74, konverentsi teesid 5.1.
  • Laane E., Panaretakis T., Buentke E., Ito K., Corcoran M., Hultenby K., Zhivotovsky B., Björklund AC., Heyman M., Söderhäll S., Mazur J., Everaus H., Porwit A., Pokrovskaja -Tamm K., Grander D. Autofaagia - deksametasooni esmane ja põhiline lüütiline toimemehhanism lümfoidsetesse rakkudesse. Eesti Arst 2008, 87 (9): 645-646, konverentsi teesid 5.2.
  • Schellekens J., Štšerbakova A., Tõns M., Everaus H., Tilanus MGJ., Aints A. NK-rakkude ekspansioon sõltub genotüübist. Eesti Arst 2008, 87 (9): 646, konverentsi teesid 5.2.
  • Kuum T., Ilves P., Ulp S., Tammik O. Preoperative CT diagnosis in pancreatic cancer. Eesti Arst 2008, 87 (10 Lisa): 714, meeting abstract 5.2.
  • Jaal, J; Dörr, W Radiation-induced late functional and fibrotic changes in mouse urinary bladder: is there a role of hypoxia? Radiotherapy and Oncology, 2008 Sept,88 (Suppl. 2):S93., konverentsi teesid 4.074
  • Jaal, J; Dörr, W Radiation Effects on Mouse Urothelium: The Possible role of Epidermal Growth Factor Receptor (EGFR) in Urothelial Restoration. International Journal of Radiation Oncology Biology Physics: Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting. Elsevier, 2008, (72(1)), S688-S689., konverentsi teesid 4.29

2007

  • Jaal J., Dörr W. Effect of recombinant human keratinocyte growth factor (rHuKGF, Palifermin) on radiation-induced mouse urinary bladder dysfunction  International journal of radiation oncology, biology, physics 2007, 69 (2): 528-533,  artikkel  1.1. 
  • Dörr W., Jaal J., Zips D. Prostate Cancer: Biological Dose Considerations and Constraints in Tele- and Brachytherapy Strahlentherapie und Onkologie 2007 Dec,183 (Spec No 2):14-15, artikkel 1.1
  • Padrik P., Kirsimägi Ü., Everaus H.  Changes in the natural history of renal cancer: comparison of Estonian data from the periods 1986-1988 and 1996-1998 International urology and nephrology 2007, 39 (1): 35-41  artikkel 1.1. 
  • Padrik P., Eelma E., Lehtsaar J.  Rinnavähi ravi arengusuunad  Eesti Arst 2007, 86 (11): 819-822,  artikkel 1.3.   
  • Aareleid T., Mägi M., Leppik K., Pokker H.  Munandivähihaigestumus Eestis 1970–2004  Eesti Arst 2007, 86 (11): 814-818,  artikkel  1.3.   
  • Richter, C.; Jaal, J.; Dörr, W. Effect of Palifermin (rHuKGF) on CD105 expression in mouse tongue during fractionated irradiation.  In: Experimentelle Strahlentherapie und Klinische Strahlenbiologie: Experimentelle Strahlentherapie und Klinische Strahlenbiologie; Dresden, Germany; 01.-03.03.07., 2007, (16), 89 - 92, konverentsi teesid 3.4
  • Jaal, J.; Dörr, W. The role of occludin, a tight junction protein, in the radiation response of mouse urothelium. Experimentelle Strahlentherapie und Klinische Strahlenbiologie: Dresden, Germany; 01-03.03.07., 2007, (16), 81 - 84, konverentsi teesid 3.4
  • Padrik P.  Renal cell carcinoma: changes in natural history and treatment of metastatic disease : Neerurakk-kartsinoom: haiguse kulu muutused ja metastaatilise haiguse ravi  Dissertationes Medicinae Universitatis Tartuensis 2007, (146): 99lk., doktoritöö  2.3.   
  • Telling S., Lehtmaa J., Kaare A., Viirsalu V., Everaus H.  8 Fr dual-lumen central venous catheter using for peripheral blood stem cell collection - single-centre experience  Bone marrow transplantation 2007, 39 (Suppl 1): S258-S258, konverentsi teesid  5.1. 
  • Jaal, Jana; Dörr, Wolfgang Radiation-induced Variations in Urothelial Expression of Uroplakin-III and Tight Junction Protein Occludin in Mouse Bladder. In: International Journal of Radiation Oncology Biology Physics: Proceedings of the American Society for Therapeutic Radiology and Oncology 49th Annual Meeting. Elsevier, 2007, (69(3)), 127 - 128, konverentsi teesid 5.1.  
  • Jaal, J.; Richter, C.; Doerr, W. Recombinant Human Keratinocyte Growth Factor (rHuKGF, Palifermin) inhibits CD105 expression in mouse tongue during fractionated irradiation. In: European Journal of Cancer: The European Cancer Conference (ECCO14); Barcelona, Spain; 23-27 September 2007. Elsevier, 2007, (5), 123, konverentsi teesid 5.1.
  • Hein M.  Dissemineeritud intravaskulaarne koagulatsioon  Lege Artis 2007, (9(66)): 10-13,  artikkel  6.3. 
  • Everaus, H. Mis on leukeemia ja lümfoom?, 6.4.
  • Orlova, S. In vitro cultivation of natural killer (NK) cells for autologous and allogenic cellular immunothreapy,  magistritöö 8

2006

  • Laane E., Derolf AR., Everaus H.  The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy  Haematologica 2006, 91 (6): 833-836,  artikkel  1.1.
  • Gruno M., Peet N., Seppet E., Kadaja L., Paju K., Eimre M., Orlova E., Peetsalu M., Tein A., Soplepmann J., Schlattner U., Peetsalu A., Seppet EK.  Oxidative phosphorylation and its coupling to mitochondrial creatine and adenylate kinases in human gastric mucosa.  Amreican Journal of Physiology-regulatory Integrative and Comparative Physiology 2006, 291 (4): R936-R946,  artikkel  1.1.
  • Jaal J., Dorr W.  Radiation induced inflammatory changes in the mouse bladder: the role of cyclooxygenase-2  J Urol 2006, 175 (4): 1529-33,  artikkel  1.1. 
  •  Jaal J., Dörr, W.  Radiation induced late damage to the barrier function of small blood vessels in mouse bladder  The Journal Of Urology [J Urol] 2006, 176 (6): 2696-2700,  artikkel  1.1.
  • Jaal J., Dorr W.  Radiation-induced damage to mouse urothelial barrier  Radiother Oncol. 2006, 80 (2): 250-256,  artikkel  1.1.
  • Vorobjova T., Ren ZG., Dunkley M., Clancy R., Maaroos HI., Labotkin R., Kull K., Uibo R.  Response of IgG1 and IgG2 subclasses to Helicobacter pylori in subjects with chronic inflammation of the gastric mucosa, atrophy and gastric cancer in a country with high Helicobacter pylori infection prevalence  APMIS 2006, 114 (5): 372-380, artikkel  1.1.
  • Grünberg H., Mikkel S.  Beeta-talasseemia  Eesti Arst 2006, 85 (10): 709-711, artikkel  1.3.
  • Everaus H.  Lümfoomidest  Eesti Arst 2006, 85 (12): 825-828  artikkel  1.3.
  • Padrik P., Saar H., Leppik K.  Tümidiini fosforülaasi ekspressiooni analüüsi rakendamine metastaatilise neeruvähiga patsientide kasvajakoes  Eesti Arst 2006, 85 (5): 297-300, artikkel  1.3.
  • Drechsler D., Deutschmann A., Jaal J., Winkler C., Baumann M., Herrmann T., Petersen C.  The importance of cyclooxegenase (COX)2 in the adjuvant radiation treatment of cervical cancers  Strahlentherapie und Onkologie 2006, 182 (Suppl. 1): 127-127,  konverentsi teesid 5.1.
  • Jaal J., Dörr W.  Radiation-induced damage to mouse urothelial barrier  Radiotherapy and Oncology 2006, 78 (Suppl. 1): 43-43,  konverentsi teesid  5.1.

2005


  • Laane E., Tani E., Bjorklund E., Elmberger G., Everaus H., Skoog L., Porwit-MacDonald A .  Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. Cytometry Part B-clinical Cytometry 2005, 64B (1): 34-42,  artikkel 1.1.
  • Everaus H., Plahhova T., Raadik A., Kongo U-K., Rätsep I., Ümarik T., Punab M., Tomberg K., Lehepuu E., Ellam S., Kullaste R.  Inimverest valmistatud ravimpreparaatide kasutamise Eesti juhend  Eesti Arst 2005, 84 (12): 897-906 ravijuhis
  • Telling S., Viirsalu V., Kaare A., Everaus H.  Peripheral stem cell collection in Estonia - review of side effects during apheresis  BONE MARROW TRANSPLANTATION 2005, 35 (S2): S322-323,  konverentsi teesid  5.1.
  • Laane E., Derolf A., Björklund E., Mazur J., Söderhäll S., Everaus H., Björkholm M., Porwit-MacDonald A.  Allogeenne luuüdi siirdamine on näidustatud ägeda müeloidse leukeemia patsientidel, kellel on leitav keemiaravi lõppedes minimaalne residuaalne haigus (MRH)  Eesti Arst 2005, 84 ( 9): 666-666  konverentsi teesid  5.2.

2004

  • Järv H., Lehtmaa J., Summerbell RC., Hoekstra ES., Samson RA., Naaber P.  Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis  Journal of Clinical Microbiology 2004, 42 (2): 925-928, artikkel 1.1.
  • Luik E., Palk K., Everaus H., Varik M., Aareleid T., Wennstrom L., Juntikka EL., Safai-Kutti S., Stockelberg D., Holmberg E,. Kutti J..  The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982-1996: a survey of patients aged > or =65 years.  Journal of Internal Medicine 2004, 256 (1): 79-85,  artikkel 1.1.
  • Sak K., Everaus H.  Nongenomic effects of 17 beta-estradiol-diversity of membrane binding sites  JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 2004, 88 (4-5): 323-335,  artikkel  1.1.
  • Jaal J., Bruchner K., Hoinkis C., Dorr W.  Radiation-induced variations in urothelial expression of intercellular adhesion molecule 1 (ICAM-1): association with changes in urinary bladder function  International Journal of Radiation Biology 2004, 80 (1): 65-72, artikkel  1.1.
  • Sjovall A., Järv V., Blomqvist L., Singnomklao T., Cedermark B., Glimelius B., Holm T.  The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study  EJSO 2004, 30 (8): 834-841,  artikkel  1.1.
  • Wennström L., Juntikka EL., Safai-Kutti S., Stockelberg D., Holmberg E., Luik E., Everaus H., Palk K., Varik M., Aareleid T., Kutti J.  The incidence and survival of acute de novo leukaemias in Estonia and in a well defined region of Western Sweden during 1982-1996: a survey of patients aged 16-64 years  Leukemia and Lymphoma 2004, 45 (5): 915-921,  artikkel  1.1.
  • Padrik P., Leppik K., Arak A.  Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study  Urologic Oncology-seminars and original investigations 2004, 22 (5): 387-392,  artikkel  1.1.
  • Aunapuu M., Pechter U., Gerskevits E., Marjamägi MM., Suuroja S., Arend A., Kolts I., Kuhnel W., Ots M.  Low-dose radiation modifies the progression of chronic renal failure  Annals of Anatomy-anatomischer anzeiger 2004, 186 (3): 277-282, artikkel  1.1.
  • Soplepmann, J., Peetsalu, M., Väli, T., Peetsalu, A.  Giant duodenal posterior wall ulcers complicated with hemorrhage: Long-term results of surgical treatment  Lithuanian Surgery 2004, 2 (4): 286-291,  artikkel  1.2.
  • Järv V., Leht M., Timberg M., Kotsar A., Šamarin A., Hirmo J., Kulla A. Eesnäärmevähi levikuulatuse määramine magnetresonantstomograafial  Eesti Arst 2004, 83 (6): 364-370,  artikkel  1.3.
  • Padrik P., Ulp S.  Rinnavähi vältimise ja ravitulemuste parandamise võimalustest Eesti Arst 2004, 83 (6): 379-383,  artikkel  1.3.
  • Mikkel, S., Vaht, K., Everaus, H.  Juveniilne krooniline müelomonotsütaarne leukeemia  Eesti Arst 2004, 83 (6): 399-402, artikkel  1.3.
  • Urbsoo K., Mikkel S., Orgulas K.  Lapseea kesknärvisüsteemi-kasvajad eestis 1991-2001  Eesti Arst 2004, 83 (5): 330,  konverentsi teesid  5.2.
  • Vaher, U., Mikkel, S., Talvik, T.  Progresseeruv paraparees neuroblastoomi esimese sümptomina. Haigusjuhu kirjeldus.  Eesti Arst 2004, 83 (5): 347,  konverentsi teesid  5.2.
  • Mikkel, S, Rägo, T.  Gaucher' tõbi: kahe haigusjuhu kirjeldus  Eesti Arst 2004, 83 (5): 354,  konverentsi teesid  5.2.
  • Labotkin, Rait  Vähk on avastatav ja ravitav : mida me peame teadma vähkkasvajatest  2004, 267 lk.  õppevahend  6.2.

2003

  • Schulman S., Rehnberg AS., Hein M., Hegedus O., Lindmarker P., Hellström PM.  Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders  Thrombosis and Haemostasis 2003, 89 (4): 741-746, artikkel 1.1.
  • Sak K., Boeynaems JM., Everaus H.  Involvement of P2Y receptors in the differentiation of haematopoietic cells  Journal of Leukocyte Biology 2003, 73 (4): 442-447,  artikkel  1.1.
  • Bouzid K., Khalfallah S., Tujakowski J., Piko B., Purkalne G., Plate S., Padrik P.., Serafy M., Pshevloutsky EM., Boussard B., Irinotecan Study Group  A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer  Annals of Oncology 2003, 14 (7): 1106-1114,  artikkel  1.1.
  • Padrik P.  Prognostic factors of immunotherapy in metastatic renal cell carcinoma Medical Oncology 2003, 20 (4): 325-334,  artikkel  1.1.
  • Vaht M., Kikas Ü., Reinart A., Lehtmaa J.  Changes in the immune system of female sunbathers due to the effect of natural UV radiation  International Journal of Hygiene and Environmental Health 2003, 206 (6): 597-599, artikkel  1.1.
  • Aunapuu M., Pechter Ü., Roosaar P., Gerskevits E., Marjamägi M., Arend A., Kolts I., Ots M.  Morphological changes in the kidney of the Wistar rat after experimental nephrectomy and effect of low-dose irradiation. Morfologicheskie izmeneniia v pochke posle 5/6 nefréktomii i vozde?stviia malykh doz radiatsii  Tsitologiia 2003, 45 (6): 555-563,  artikkel  1.1.
  • Soplepmann J.  Peptic ulcer haemorrhage in Estonia: epidemiology, prognostic factors, treatment and outcome  Dissertationes medicinae Universitatis Tartuensis 2003, (86): 1-139,  doktoritöö  2.3.
  • Padrik P., Saar H., Leppik K., Arak A.  Thymidine phosphorylase (TP) expression in tumor cells of metastatic renal cell carcinoma (RCC) patients treated with capecitabine and interferon-alfa2A (IFNa). 12th European Cancer Conference, Sept. 21-25, 2003, Copenhagen, Denmark  European Journal of Cancer Supplements 2003, 1 (5): S261, konverentsi teesid  5.1.
  • Arak A., Leppik K.  Combination of complete cytoreductive surgery, intraperitoneal and systemic chemotherapy in advanced gastric cancer patients with peritoneal carcinomatosis: feasibility and preliminary results  Gastric cancer in the world 2003. Proceeding of fifth international gastric cancer congress (eds. Santoro E., Garofalo A.) 2003, 157,  konverentsi teesid  5.2.
  • Padrik P., Leppik K., Arak A.  A phase II study of combination therapy with capecitabine and interferon-alfa2A (IFNa) in patients with metastatic renal cell carcinoma (RCC)  Meeting Proceedings American Society of Clinical Oncology 2003, 22 405,  konverentsi teesid 5.2.
  • Labotkin R.  Haigestumus kolorektaarsesse vähki Eestis  Eesti Arst 2003, 82 (9): 636,  konverentsi teesid  5.2.
  • Suija H., Labotkin R., Suija K.  Onkoloogilistele haigetele Eestis 10 aasta jooksul (1993-2002) korraldatud kohanemiskursuste kvalitatiivne analüüs  Eesti Arst 2003, 82 (9): 654,  konverentsi teesid  5.2.
  • Labotkin R.  -  Kuidas suhelda raske haige ja tema sugulastega: valikkursus arstiteaduskonna üliõpilastele 2003, 1-69  õppematerjal  6.2.

2002

  • Sillakivi T., Lang A., Soplepmann J., Tein A., Peetsalu A.  Incidence of perforated peptic ulcer correlated with suicide rate in Estonia in 1981-2000  Proceedings of the Eurosurgery 2002 2002, 199-204,  artikkel  1.1.
  • Padrik P.  Metastaatilise neeruvähi süsteemne ravi  Eesti Arst 2002, 81 (10): 631-637,  artikkel  1.3.
  • Sak K., Everaus H.  Metabotroopsed nukleotiidi retseptorid perifeerses veres ja vereloomes  Eesti Arst 2002, 81 (2): 88-92,  artikkel  1.3.
  • Sak K., Everaus H.  Metabotroopsed nukleotiidi retseptorid perifeerses veres ja vereloomes  Eesti Arst 2002, 81 (2): 88-92, artikkel  1.3.
  • Viigimaa I. Mikkel S.  Lümfadenopaatia lapsel  Eesti Arst 2002, 81 (3): 148-151, artikkel  1.3.
  • Soplepmann J., Peetsalu M., Sillakivi T., Tein A., Väli T., Peetsalu A.  Muutused peptilise haavandi verejooksu ravis  Eesti Arst 2002, 81 (8): 468-472,  artikkel  1.3.
  • Kallas A., Talpsep T., Everaus H.  Changes in epitope specificity and in distribution of IgG subtypes of FVIII antibodies during immune tolerance therapy (ITT) in hemophilia. A patients with FVIII antibodies - a case report.  31st Hemophilia Symposium: Hamburg 2000 (eds. Scharrer I., Schramn W.) 2002, 23-40, artikkel 3.4. * Ojamaa J., Raven I., Ojamaa A.  Renal cell carcinoma: diagnostics at the division of oncology of the Tartu University Clinics during the two last decades  International Journal of Cancer 2002, (Suppl. 13): 365,  konverentsi teesid  5.1.
  • Järv H., Lehtmaa J., Naaber P.  Aspergillus sp. Positiivne verekülv - esimene märk invasiivsest aspergilloosist  Eesti Arst 2002, 81 (9): 564  konverentsi teesid  5.2.
    Viigimaa I., Lehtmaa J., Everaus H.  CD44 ekspressiooni tase normaalsete ja kasvajaliste B-lümfotsüütide membraanil. Eesti Arst 2002, 81 (9): 595,  konverentsi teesid